Nice FiercePharma article on this news:
"With FDA nod, Pfizer and Astellas’ Xtandi gets its shot at blockbuster sales boost"
A couple tid-bits from this article that I didn't know before:
1) Pfizer/Astellas are running two other enzalutamide prostate cancer trials: Arches (metastatic) due out in 2020 and Embark (non-metastatic) due out in 2021. Both trials are in patients with hormone sensitive disease (as opposed to the castrate resistant prostate cancer (CRPC)). If ZEN-3694 proves itself as a good combo partner with enzalutamide for CRPC, then perhaps more coat tail riding will occur for the hormone sensitive varieties......
2) ERLEADA™ (apalutamide), a next generation androgen receptor inhibitor from Janssen/J&J, is currently approved for non-metastatic CRPC. So enzalutamide (also an androgen receptor inhibitor) and apalutamide will now go head to head for non-metastatic CRPC. I think apalutamide is still in trials for metastatic CRPC. Perhaps it won't be long before we see some ZEN-3694/apalutamide combo trials..........
